Emily Podany, MD

Medical Oncologist

Emily Podany

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Emily Podany, MD

Watch video on YouTube

Emily Podany, MD

5 mins

Emily Podany, MD, Medical Oncologist from Siteman Cancer Center, discusses how breast cancer is a completely different disease today than it was 10 to 20 years ago. Treatments have evolved significantly, changing the way breast cancer is diagnosed and treated. Advancements in breast cancer care are happening rapidly, with new developments, new drugs, and new opportunities emerging every six months, including less intensive therapies than were available even five years ago. She also shares how more and more tests are being developed to help determine exactly which treatments will work best for each patient’s cancer, as well as how long treatment may be needed. All of these advancements are coming together to create a more personalized approach to breast cancer care than ever before.

Clinical Expertise

  • Medical Oncology

Primary Academic Title

Assistant Professor of Medicine, Division of Medical Oncology, WashU Medicine

Board Certification

  • 2022: American Board of Internal Medicine

Training

  • 2022 - 2025: Clinical Fellow, WashU Medicine, St. Louis, MO
  • 2023 - 2025: Hematology/Oncology Fellow Wellness Leader, WashU Medicine, St. Louis, MO

Education

  • 2011: BA, WashU Medicine, St. Louis, MO
  • 2018: MD, Baylor College of Medicine, Houston, TX
  • 2025: MPHS, WashU Medicine, St. Louis, MO

Research & Selected Publications

Research Interest

Identifying and improving racial and socioeconomic health disparities in screening, diagnosis, treatment, and outcomes in patients with breast cancer. Circulating tumor DNA, precision medicine, and improving targeted treatment use in patients with metastatic breast cancer.

Research Publications

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer
Authors:

Lloyd MR, Chica-Parrado R, Weipert CM, one or more additional authors omitted Podany EL, one or more additional authors omitted Wander SA

Journal & Year:

EBioMedicine | 2025

Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer
Authors:

Podany EL, Foffano L, Gerratana L, one or more additional authors omitted Davis AA

Journal & Year:

JAMA Netw Open | 2025